-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] On March 25, the pharmaceutical sector changed, and many stocks hit the daily limit, including Essence Pharmaceutical, Qizheng Tibetan Medicine, Sinopharm, Sailong Pharmaceutical, Watson Pharmaceutical, Guizhou Bailing, etc.
In terms of sectors, it mainly focuses on sectors such as APIs and traditional Chinese medicines
.
Essence Pharma At 9:30 on March 25, Essence Pharma opened the daily limit at 28.
8 yuan, and gained 6 boards in 8 days
.
The stock has risen by the limit 30 times in the past year
.
The company is mainly engaged in the research and development, production and sales of traditional Chinese patent medicine preparations, chemical raw materials and intermediates, chemical and pharmaceutical intermediates, Chinese herbal medicines and Chinese herbal decoction pieces, and biopharmaceuticals
.
In the first three quarters of 2021, the company achieved operating income of 969 million yuan, a year-on-year increase of 4.
69%; net profit attributable to shareholders of listed companies was 128 million yuan, a year-on-year increase of 26.
32%; basic earnings per share was 0.
1577 yuan / share
.
On the news, the company announced overnight that it will enjoy 12% of its net profit in the future after betatinib, which it participated in, is listed and sold
.
Qizheng Tibetan Medicine On March 25, Qizheng Tibetan Medicine opened at 27.
79 yuan.
As of 09:39, the stock rose 10% to 29.
27 yuan, closing the price limit
.
According to the data, the company is mainly engaged in the research and development, production and sales of Tibetan medicines, including topical analgesics and oral Tibetan medicines
.
The third quarterly report of 2021 shows that in the first three quarters, Qizheng Tibetan Medicine achieved operating income of 1.
18927 billion yuan, and net profit attributable to shareholders of the parent company was 647.
39 million yuan, a year-on-year increase of 99.
8146%.
Basic earnings per share were 1.
2247 yuan
.
Sinopharm As of 09:41, Sinopharm's intraday daily limit was reported at 33.
62 yuan
.
The company is a pharmaceutical distribution enterprise.
Its main products include wholesale Chinese patent medicines, chemical preparations, chemical raw materials, antibiotics, and biochemical medicines
.
The 2021 annual report shows that the company achieved operating income of 46.
469 billion yuan, a year-on-year increase of 15.
08%, net profit of 1.
754 billion yuan, a year-on-year increase of 26.
86%, and basic earnings per share of 2.
32 yuan
.
Sailong Pharmaceuticals As of 09:40, the daily limit of Sailong Pharmaceuticals was reported at 16.
52 yuan
.
It is worth mentioning that the stock has risen by the limit 11 times in the past year
.
The company belongs to the pharmaceutical manufacturing industry, and has now become a modern pharmaceutical enterprise integrating the research and development, production, marketing and technical services of pharmaceutical intermediates, APIs and preparations with the entire pharmaceutical industry chain
.
The 2021 annual performance forecast shows that in 2021, the company’s net profit attributable to shareholders of listed companies will be 8.
75 million yuan – 17.
5 million yuan, a decrease from the loss in the same period of the previous year
.
Watson Pharmaceuticals At 09:26 on March 25, Watson Pharmaceuticals opened the daily limit at 19.
46 yuan
.
The stock has risen by the limit 14 times in the past year
.
The company is mainly engaged in the research and development, production and sales of chemical medicines and Chinese patent medicines, focusing on the research and development, production and sales of Chinese patent medicines and chemical medicines
.
According to the third quarterly report of 2021, the operating income of Watson Pharmaceuticals was 645.
34 million yuan, the net profit attributable to shareholders of the parent company was 89.
43623 million yuan, a year-on-year decrease of 5.
6391%, and the basic earnings per share was 0.
223 yuan
.
Guizhou Bailing On February 25, Guizhou Bailing opened at 6.
93 yuan.
As of 09:34, the stock rose 10% to 7.
48 yuan, closing the upper limit
.
It is reported that the stock has risen by the limit 3 times in the past year
.
The company's main business is the research and development, production and sales of Miao medicine
.
The main products are Yindan Xinnaotong Soft Capsules, Vitamin C Yinqiao Tablets, Kesuting Syrup and Capsules, Xiaoer Chaigui Ture Granules, Jingan Capsules, Shuangyanghou Bitong Granules, Milinqing Capsules, Kangfuling Capsules, Compound Goldenrod Spray, Jingdaining Capsules, Xiaoke Granules, Tangning Tongluo Capsules/Tablets, Fertilizer, Purified Water
.
According to the third quarterly report of 2021, Guizhou Bailing achieved an operating income of 1.
97826 billion yuan, a net profit attributable to shareholders of the parent company of 120.
67 million yuan, a year-on-year decrease of 25.
0546%, and a basic earnings per share of 0.
09 yuan
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
In terms of sectors, it mainly focuses on sectors such as APIs and traditional Chinese medicines
.
Essence Pharma At 9:30 on March 25, Essence Pharma opened the daily limit at 28.
8 yuan, and gained 6 boards in 8 days
.
The stock has risen by the limit 30 times in the past year
.
The company is mainly engaged in the research and development, production and sales of traditional Chinese patent medicine preparations, chemical raw materials and intermediates, chemical and pharmaceutical intermediates, Chinese herbal medicines and Chinese herbal decoction pieces, and biopharmaceuticals
.
In the first three quarters of 2021, the company achieved operating income of 969 million yuan, a year-on-year increase of 4.
69%; net profit attributable to shareholders of listed companies was 128 million yuan, a year-on-year increase of 26.
32%; basic earnings per share was 0.
1577 yuan / share
.
On the news, the company announced overnight that it will enjoy 12% of its net profit in the future after betatinib, which it participated in, is listed and sold
.
Qizheng Tibetan Medicine On March 25, Qizheng Tibetan Medicine opened at 27.
79 yuan.
As of 09:39, the stock rose 10% to 29.
27 yuan, closing the price limit
.
According to the data, the company is mainly engaged in the research and development, production and sales of Tibetan medicines, including topical analgesics and oral Tibetan medicines
.
The third quarterly report of 2021 shows that in the first three quarters, Qizheng Tibetan Medicine achieved operating income of 1.
18927 billion yuan, and net profit attributable to shareholders of the parent company was 647.
39 million yuan, a year-on-year increase of 99.
8146%.
Basic earnings per share were 1.
2247 yuan
.
Sinopharm As of 09:41, Sinopharm's intraday daily limit was reported at 33.
62 yuan
.
The company is a pharmaceutical distribution enterprise.
Its main products include wholesale Chinese patent medicines, chemical preparations, chemical raw materials, antibiotics, and biochemical medicines
.
The 2021 annual report shows that the company achieved operating income of 46.
469 billion yuan, a year-on-year increase of 15.
08%, net profit of 1.
754 billion yuan, a year-on-year increase of 26.
86%, and basic earnings per share of 2.
32 yuan
.
Sailong Pharmaceuticals As of 09:40, the daily limit of Sailong Pharmaceuticals was reported at 16.
52 yuan
.
It is worth mentioning that the stock has risen by the limit 11 times in the past year
.
The company belongs to the pharmaceutical manufacturing industry, and has now become a modern pharmaceutical enterprise integrating the research and development, production, marketing and technical services of pharmaceutical intermediates, APIs and preparations with the entire pharmaceutical industry chain
.
The 2021 annual performance forecast shows that in 2021, the company’s net profit attributable to shareholders of listed companies will be 8.
75 million yuan – 17.
5 million yuan, a decrease from the loss in the same period of the previous year
.
Watson Pharmaceuticals At 09:26 on March 25, Watson Pharmaceuticals opened the daily limit at 19.
46 yuan
.
The stock has risen by the limit 14 times in the past year
.
The company is mainly engaged in the research and development, production and sales of chemical medicines and Chinese patent medicines, focusing on the research and development, production and sales of Chinese patent medicines and chemical medicines
.
According to the third quarterly report of 2021, the operating income of Watson Pharmaceuticals was 645.
34 million yuan, the net profit attributable to shareholders of the parent company was 89.
43623 million yuan, a year-on-year decrease of 5.
6391%, and the basic earnings per share was 0.
223 yuan
.
Guizhou Bailing On February 25, Guizhou Bailing opened at 6.
93 yuan.
As of 09:34, the stock rose 10% to 7.
48 yuan, closing the upper limit
.
It is reported that the stock has risen by the limit 3 times in the past year
.
The company's main business is the research and development, production and sales of Miao medicine
.
The main products are Yindan Xinnaotong Soft Capsules, Vitamin C Yinqiao Tablets, Kesuting Syrup and Capsules, Xiaoer Chaigui Ture Granules, Jingan Capsules, Shuangyanghou Bitong Granules, Milinqing Capsules, Kangfuling Capsules, Compound Goldenrod Spray, Jingdaining Capsules, Xiaoke Granules, Tangning Tongluo Capsules/Tablets, Fertilizer, Purified Water
.
According to the third quarterly report of 2021, Guizhou Bailing achieved an operating income of 1.
97826 billion yuan, a net profit attributable to shareholders of the parent company of 120.
67 million yuan, a year-on-year decrease of 25.
0546%, and a basic earnings per share of 0.
09 yuan
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
